COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the World Health Organization (WHO), Gavi the Vaccine Alliance and The Coalition for Epidemic Preparedness Innovations (CEPI) aims to start shipping nearly 90 million COVID-19 vaccine doses to the continent in February, in what will be Africa’s largest ever mass vaccination campaign.
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO. The organization is currently reviewing the vaccine and the outcome of the review is expected soon.
“Africa has watched other regions start COVID-19 vaccination campaigns from the side-lines for too long. This planned roll-out is a critical first step to ensuring the continent gets equitable access to vaccines,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We know no one will be safe until everyone is safe.”
COVAX notified countries through letters which were sent on 30 January 2021. Amid surging demand for COVID-19 vaccines, the final shipments will be based on production capacities of vaccine manufacturers and the readiness of countries. Recipient countries are required to submit finalized national deployment and vaccination plans to receive vaccines from the COVAX facility.
In addition, around 320 000 doses of the Pfizer-BioNTech vaccine have been allocated to four African countries -Cabo Verde, Rwanda, South Africa and Tunisia. This vaccine has received WHO Emergency Use Listing but requires countries to be able to store and distribute doses at minus 70 degrees Celsius. To access an initial limited volume of Pfizer vaccine, countries were invited to submit proposals. Thirteen African countries submitted proposals and were evaluated by a multi-agency committee based on current mortality rates, new cases and trends, and the capacity to handle the ultra-cold chain needs of the vaccine.